{"id":34758,"date":"2026-03-20T18:02:18","date_gmt":"2026-03-20T12:32:18","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=34758"},"modified":"2026-03-25T13:22:59","modified_gmt":"2026-03-25T07:52:59","slug":"emerging-radioligand-therapies-in-clinical-trials","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/emerging-radioligand-therapies-in-clinical-trials","title":{"rendered":"The Next Wave of Radioligand Therapies: 5 Candidates to Watch"},"content":{"rendered":"\n<p><strong><em>Summary<\/em><\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><em>Radioligand therapy is quickly establishing itself as a transformative force in oncology, with demand accelerating so rapidly that manufacturers are under pressure to scale up production.<\/em><\/li>\n\n\n\n<li><em>Among the leaders, Novartis is advancing its late-stage candidate 225Ac-PSMA-617, while a growing competitive landscape is taking shape.<\/em><\/li>\n\n\n\n<li><em>Companies such as Curium Pharma (177Lu-PSMA-I&amp;T), ITM Isotope Technologies (ITM-11), Fusion Pharmaceuticals (FPI-2265), and Clarity Pharmaceuticals (67Cu-SAR-bisPSMA) are progressing promising assets through mid- to late-stage development.<\/em><\/li>\n\n\n\n<li><em>Key players, including Bayer, ARTBIO, Convergent Therapeutics, Perspective Therapeutics, PRECIRIX, Ariceum Therapeutics, and Nuclidium, are also driving innovation across prostate cancer, breast cancer, and a broad range of solid tumors.<\/em><\/li>\n<\/ul>\n\n\n\n<p>Radioligand therapy is rapidly emerging as a true game-changer in oncology, so much so that manufacturers are racing against the clock to keep up with demand. This urgency underscores its powerful, transformative potential in reshaping cancer care.<\/p>\n\n\n\n<p>Traditional treatment approaches often fall short for patients with rare, treatment-resistant, or metastatic cancers. <a href=\"https:\/\/www.delveinsight.com\/blog\/radioligand-therapies-in-cancer-treatment\">Radioligand therapy<\/a> is stepping in to bridge this gap, offering a promising, life-enhancing option for those with limited alternatives. By delivering precision-targeted treatment, it is redefining the future of personalized cancer care.<\/p>\n\n\n\n<p><em>Sadaf Javed, Manager of Forecasting at DelveInsght, notes that the currently approved systemic radiotherapeutics are primarily Lu-177\u2013based beta-emitting radioligand therapies, notably PLUVICTO and LUTATHERA. Novartis remains the dominant commercial player and a major purchaser of Lu-177 to support these products and its expanding radioligand therapy pipeline, as per Javed. However, the field is rapidly evolving, with numerous Lu-177\u2013based candidates in development and increasing investment in next-generation alpha-emitting isotopes such as Actinium-225 and Lead-212, Javed further added.<\/em><\/p>\n\n\n\n<p>Novartis is pushing the boundaries of radioligand therapy with its late-stage frontrunner <strong>225Ac-PSMA-617<\/strong>. Meanwhile, a competitive wave is building, as players such as <strong>Curium Pharma<\/strong> (177Lu-PSMA-I&amp;T), <strong>ITM Isotope Technologies <\/strong>(ITM-11), <strong>Fusion Pharmaceuticals <\/strong>(FPI-2265), and <strong>Clarity Pharmaceuticals<\/strong> (67Cu-SAR-bisPSMA) advance promising candidates into mid- to late-stage development.<\/p>\n\n\n\n<p>Let\u2019s dive deep into the assessment of these 5 promising <a href=\"https:\/\/www.delveinsight.com\/report-store\/radioligand-therapies-market-forecast\">emerging radioligand therapies<\/a> poised to make a meaningful impact in prostate cancer and neuroendocrine tumors.<\/p>\n\n\n\n<p><strong>Novartis\u2019 225Ac\u2011PSMA\u2011617<\/strong><\/p>\n\n\n\n<p><em>Phase III<\/em><\/p>\n\n\n\n<p>Building on the success of beta\u2011emitting PSMA\u2011617, Novartis and academic collaborators are advancing 225Ac\u2011PSMA\u2011617 as an alpha\u2011emitting radioligand therapy for advanced prostate cancer. Actinium\u2011225 delivers a highly potent, short\u2011range alpha radiation payload that can intensify tumor cell killing while limiting collateral damage to surrounding tissues.<\/p>\n\n\n\n<p>Early clinical experience suggests that 225Ac\u2011PSMA\u2011617 can achieve deep prostate\u2011specific antigen (PSA) responses, including \u226550% reductions in PSA in the majority of treated patients, with manageable toxicity characterized by low\u2011grade xerostomia. Notably, 225Ac\u2011PSMA\u2011617 has also been explored as a \u201csalvage\u201d or escalation option following 177Lu\u2011PSMA\u2011617 failure, where combination or sequential approaches have produced encouraging disease control rates and a favorable benefit\u2013risk profile. As more robust randomized data emerge, 225Ac\u2011PSMA\u2011617 could redefine how clinicians sequence beta\u2011 and alpha\u2011based PSMA therapies in mCRPC.<\/p>\n\n\n\n<p><strong>Curium Pharma\u2019s 177Lu-PSMA-I&amp;T<\/strong><\/p>\n\n\n\n<p><em>Phase III<\/em><\/p>\n\n\n\n<p>Curium\u2019s 177Lu-PSMA-I&amp;T is rapidly emerging as a frontrunner among next-generation PSMA-targeted radioligand therapies for metastatic castration-resistant prostate cancer\u2014and it\u2019s now advancing into pivotal territory in China. With the Centre for Drug Evaluation (CDE) accepting Curium Shanghai\u2019s IND application, the path is clear for a registrational Phase 3 bridging study in Chinese patients.<\/p>\n\n\n\n<p>This open-label, randomized trial will evaluate 177Lu-PSMA-I&amp;T against standard hormone therapy in ~60 patients, building on robust global data, including insights from the <strong>Phase 3 ECLIPSE study<\/strong>. If successful, this effort could accelerate access to cutting-edge PSMA-targeted RLT in China and reinforce lutetium-based therapies as a cornerstone in advanced <a href=\"https:\/\/www.delveinsight.com\/report-store\/prostate-cancer-market-insight\">prostate cancer treatment<\/a>.<\/p>\n\n\n\n<p>Further strengthening its position, Curium Pharma completed the acquisition of <strong>Eczac\u0131ba\u015f\u0131-Monrol\u2019s nuclear business<\/strong> in March 2025, significantly boosting its Lu-177 manufacturing capabilities to support rising global demand and upcoming launches in prostate cancer and neuroendocrine tumor indications.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"412\" src=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/03\/Emerging-Radioligand-Therapies-1024x412.webp\" alt=\"Emerging-Radioligand-Therapies\" class=\"wp-image-34760\" srcset=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/03\/Emerging-Radioligand-Therapies-1024x412.webp 1024w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/03\/Emerging-Radioligand-Therapies-300x121.webp 300w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/03\/Emerging-Radioligand-Therapies-150x60.webp 150w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/03\/Emerging-Radioligand-Therapies-768x309.webp 768w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/03\/Emerging-Radioligand-Therapies-1536x618.webp 1536w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/03\/Emerging-Radioligand-Therapies.webp 1920w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p><strong>ITM Isotope Technologies\u2019 ITM-11<\/strong><\/p>\n\n\n\n<p><em>Phase III<\/em><\/p>\n\n\n\n<p>ITM\u201111 (n.c.a. 177Lu\u2011edotreotide) is an innovative targeted radionuclide therapy designed for patients with gastroenteropancreatic neuroendocrine tumors (GEP\u2011NETs), a heterogeneous group of typically late\u2011diagnosed tumors with limited systemic options. ITM\u201111 couples the somatostatin analog edotreotide (DOTATOC) with no\u2011carrier\u2011added lutetium\u2011177, delivering beta radiation directly to somatostatin receptor\u2013positive tumor cells while minimizing exposure to normal tissues.<\/p>\n\n\n\n<p>\u200bITM\u201111 has demonstrated a favorable safety profile and promising efficacy, including significantly extended progression\u2011free survival and high tumor\u2011to\u2011kidney ratios in earlier studies, which earned <strong>orphan designation<\/strong> for <a href=\"https:\/\/www.delveinsight.com\/report-store\/gastroenteropancreatic-neuroendocrine-tumors-gep-nets-market\">GEP\u2011NETs treatment<\/a>. The agent is now in two <strong>Phase 3 trials: COMPETE <\/strong>for Grade 1\u20132 GEP\u2011NETs and<strong> COMPOSE <\/strong>for well\u2011differentiated high\u2011grade disease. It is supported by positive COMPETE results and an accepted FDA New Drug Application (NDA), with a <strong>Prescription Drug User Fee Act (PDUFA) goal date of August 28, 2026<\/strong>. If approved, ITM\u201111 could become a new standard RLT option across a broad spectrum of GEP\u2011NET patients.<\/p>\n\n\n\n<p><strong>Fusion\u2019s FPI-2265&nbsp;<\/strong><\/p>\n\n\n\n<p><em>Phase II<\/em><\/p>\n\n\n\n<p>Fusion Pharmaceuticals\u2019 FPI\u20112265 is an actinium\u2011225\u2013based PSMA\u2011targeted radioconjugate that exemplifies the field\u2019s shift toward alpha\u2011emitting RLTs in prostate cancer. Targeting PSMA with a 225Ac payload, FPI\u20112265 is being evaluated in patients with mCRPC in the <strong>Phase 2 TATCIST trial <\/strong>and in the <strong>Phase 2\/3 AlphaBreak<\/strong> registrational program.<\/p>\n\n\n\n<p>The TATCIST and AlphaBreak trials are designed to include both PSMA\u2011RLT\u2013na\u00efve patients and those previously treated with 177Lu\u2011based PSMA agents such as PLUVICTO, positioning FPI\u20112265 as a potential option across multiple lines of therapy. Early data from TATCIST and the initiation of the AlphaBreak trial underscore the promise of alpha\u2011based PSMA targeting to deliver more potent, focused radiation to resistant disease while maintaining a manageable safety profile. As Fusion builds out its manufacturing and actinium\u2011225 supply infrastructure, FPI\u20112265 could emerge as a leading alpha RLT in the <a href=\"https:\/\/www.delveinsight.com\/report-store\/metastatic-castration-resistant-prostate-cancer-mcrpc-market\">mCRPC landscape<\/a>.<\/p>\n\n\n\n<p><strong>Clarity\u2019s 67Cu-SAR-bisPSMA<\/strong><\/p>\n\n\n\n<p><em>Phase II<\/em><\/p>\n\n\n\n<p>Clarity Pharmaceuticals\u2019 67Cu\u2011SAR\u2011bisPSMA brings a distinct copper\u2011based theranostic platform to the PSMA RLT arena. The agent is being investigated in SECuRE, a US <strong>Phase I\/IIa trial<\/strong> in mCRPC, where patients receive escalating single doses of 67Cu\u2011SAR\u2011bisPSMA after diagnostic imaging with 64Cu\u2011SAR\u2011bisPSMA. Initial cohorts at 4, 8, and 12 GBq have shown no dose\u2011limiting toxicities and compelling signals of antitumor activity, including marked reductions in PSMA PET uptake and PSA declines.<\/p>\n\n\n\n<p>In one notable SECuRE case, a patient receiving two cycles of 8 GBq achieved a complete response by RECIST, with PSA falling from 47.2 ng\/mL to undetectable levels and complete resolution of PSMA uptake on 64Cu\u2011SAR\u2011bisPSMA PET imaging. Reflecting the strength of early data and the high unmet need in mCRPC, the FDA has granted Fast Track Designation to 67Cu\u2011SAR\u2011bisPSMA, the third <strong>Fast Track<\/strong> for Clarity\u2019s SAR\u2011bisPSMA platform within six months, supporting a strategy to move the product into large pre\u2011chemotherapy mCRPC populations and combinations with androgen receptor pathway inhibitors. Coupled with Clarity\u2019s proprietary SAR chelator technology and streamlined copper\u201164\/67 supply model, 67Cu\u2011SAR\u2011bisPSMA could help address the scalability challenges that have historically constrained PSMA\u2011RLT access.<\/p>\n\n\n\n<p>Beyond the frontrunners, a strong pipeline is rapidly taking shape across the <a href=\"https:\/\/www.delveinsight.com\/blog\/radioligand-therapies-in-cancer-treatment\">radioligand therapy landscape<\/a>. Industry players like <strong>Bayer <\/strong>(225Ac-PSMA-Trillium, 225Ac-Pelgifatamab, 225Ac-GPC3), <strong>ARTBIO<\/strong> (212Pb-NG001), <strong>Convergent Therapeutics<\/strong> (CONV01-\u03b1), <strong>Perspective Therapeutics<\/strong> (VMT-\u03b1-NET, VMT01, PSV359), <strong>PRECIRIX <\/strong>(CAM-FAP-Ac-225), <strong>Ariceum Therapeutics<\/strong> (225Ac-SSO110, ATT001), and <strong>Nuclidium<\/strong> (NU101, NU201) are all advancing innovative candidates across prostate cancer, breast cancer, and a wide spectrum of solid tumors.<\/p>\n\n\n\n<p>In conclusion, these emerging RLTs highlight how rapidly the field is evolving, from beta to alpha emitters, from lutetium to copper, and from late\u2011line salvage therapy toward earlier disease settings and broader tumor types. As pivotal data readouts and regulatory milestones approach over the next few years, oncologists may soon have a much richer, more personalized toolbox of radioligand options to match individual tumor biology, treatment history, and logistical realities.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/radioligand-therapies-market-forecast\"><img decoding=\"async\" width=\"1024\" height=\"194\" src=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/03\/Radioligand-Therapies-Market-Outlook-1024x194.webp\" alt=\"Radioligand Therapies Market Outlook\" class=\"wp-image-34670\" srcset=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/03\/Radioligand-Therapies-Market-Outlook-1024x194.webp 1024w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/03\/Radioligand-Therapies-Market-Outlook-300x57.webp 300w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/03\/Radioligand-Therapies-Market-Outlook-150x28.webp 150w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/03\/Radioligand-Therapies-Market-Outlook-768x145.webp 768w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/03\/Radioligand-Therapies-Market-Outlook-1536x291.webp 1536w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/03\/Radioligand-Therapies-Market-Outlook.webp 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>Summary Radioligand therapy is rapidly emerging as a true game-changer in oncology, so much so that manufacturers are racing against the clock to keep up with demand. This urgency underscores its powerful, transformative potential in reshaping cancer care. Traditional treatment approaches often fall short for patients with rare, treatment-resistant, or metastatic cancers. Radioligand therapy is [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":34765,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[22929,18415,498,22073,22915,22917],"industry":[17225],"therapeutic_areas":[17228],"class_list":["post-34758","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-emerging-radioligand-therapies","tag-lutathera","tag-prostate-cancer","tag-radioligand-therapies","tag-radioligand-therapies-treatment","tag-rlts","industry-pharmaceutical","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>5 Emerging Radioligand Therapies Poised to Transform Oncology<\/title>\n<meta name=\"description\" content=\"Among the leaders, Novartis is advancing its late-stage candidate 225Ac-PSMA-617, while a growing competitive landscape is taking shape.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/emerging-radioligand-therapies-in-clinical-trials\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"5 Emerging Radioligand Therapies Poised to Transform Oncology\" \/>\n<meta property=\"og:description\" content=\"Among the leaders, Novartis is advancing its late-stage candidate 225Ac-PSMA-617, while a growing competitive landscape is taking shape.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/emerging-radioligand-therapies-in-clinical-trials\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-20T12:32:18+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-25T07:52:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/03\/emerging-radioligand-therapies-in-clinical-trials.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"466\" \/>\n\t<meta property=\"og:image:height\" content=\"284\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"5 Emerging Radioligand Therapies Poised to Transform Oncology","description":"Among the leaders, Novartis is advancing its late-stage candidate 225Ac-PSMA-617, while a growing competitive landscape is taking shape.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/emerging-radioligand-therapies-in-clinical-trials","og_locale":"en_US","og_type":"article","og_title":"5 Emerging Radioligand Therapies Poised to Transform Oncology","og_description":"Among the leaders, Novartis is advancing its late-stage candidate 225Ac-PSMA-617, while a growing competitive landscape is taking shape.","og_url":"https:\/\/www.delveinsight.com\/blog\/emerging-radioligand-therapies-in-clinical-trials","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2026-03-20T12:32:18+00:00","article_modified_time":"2026-03-25T07:52:59+00:00","og_image":[{"width":466,"height":284,"url":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/03\/emerging-radioligand-therapies-in-clinical-trials.webp","type":"image\/webp"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/emerging-radioligand-therapies-in-clinical-trials","url":"https:\/\/www.delveinsight.com\/blog\/emerging-radioligand-therapies-in-clinical-trials","name":"5 Emerging Radioligand Therapies Poised to Transform Oncology","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/emerging-radioligand-therapies-in-clinical-trials#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/emerging-radioligand-therapies-in-clinical-trials#primaryimage"},"thumbnailUrl":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/03\/emerging-radioligand-therapies-in-clinical-trials.webp","datePublished":"2026-03-20T12:32:18+00:00","dateModified":"2026-03-25T07:52:59+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"Among the leaders, Novartis is advancing its late-stage candidate 225Ac-PSMA-617, while a growing competitive landscape is taking shape.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/emerging-radioligand-therapies-in-clinical-trials"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/emerging-radioligand-therapies-in-clinical-trials#primaryimage","url":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/03\/emerging-radioligand-therapies-in-clinical-trials.webp","contentUrl":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/03\/emerging-radioligand-therapies-in-clinical-trials.webp","width":466,"height":284,"caption":"emerging-radioligand-therapies-in-clinical-trials"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/03\/emerging-radioligand-therapies-in-clinical-trials-300x183.webp","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Emerging Radioligand Therapies<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Lutathera<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Prostate Cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">radioligand therapies<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Radioligand Therapies Treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">RLTs<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Emerging Radioligand Therapies<\/span>","<span class=\"advgb-post-tax-term\">Lutathera<\/span>","<span class=\"advgb-post-tax-term\">Prostate Cancer<\/span>","<span class=\"advgb-post-tax-term\">radioligand therapies<\/span>","<span class=\"advgb-post-tax-term\">Radioligand Therapies Treatment<\/span>","<span class=\"advgb-post-tax-term\">RLTs<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 2 months ago","modified":"Updated 1 month ago"},"absolute_dates":{"created":"Posted on Mar 20, 2026","modified":"Updated on Mar 25, 2026"},"absolute_dates_time":{"created":"Posted on Mar 20, 2026 6:02 pm","modified":"Updated on Mar 25, 2026 1:22 pm"},"featured_img_caption":"emerging-radioligand-therapies-in-clinical-trials","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/34758","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=34758"}],"version-history":[{"count":6,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/34758\/revisions"}],"predecessor-version":[{"id":34853,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/34758\/revisions\/34853"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/34765"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=34758"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=34758"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=34758"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=34758"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=34758"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}